Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TCON

TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis

TRACON Pharmaceuticals logo

About TRACON Pharmaceuticals Stock (NASDAQ:TCON)

Advanced Chart

Key Stats

Today's Range
$0.03
$0.05
50-Day Range
$0.02
$0.08
52-Week Range
$0.00
$14.75
Volume
23,886 shs
Average Volume
120,908 shs
Market Capitalization
$109.80 thousand
P/E Ratio
0.01
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TCON Stock News Headlines

NVIDIA's Worst Nightmare?
$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the REAL fortune they expect to come from quantum computing - a $2 trillion explosion by 2035. The kicker? One company is America's FIRST commercial supplier of the material that makes it possible.tc pixel
Q1 2024 TRACON Pharmaceuticals Inc Earnings Call
See More Headlines

TCON Stock Analysis - Frequently Asked Questions

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its quarterly earnings data on Tuesday, May, 14th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing the consensus estimate of ($1.20) by $0.13. The biopharmaceutical company earned $0.10 million during the quarter.

TRACON Pharmaceuticals's stock reverse split on the morning of Wednesday, April 10th 2024.The 1-20 reverse split was announced on Wednesday, April 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

TRACON Pharmaceuticals (TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that TRACON Pharmaceuticals investors own include NVIDIA (NVDA), SCYNEXIS (SCYX), Micron Technology (MU), Advanced Micro Devices (AMD), OPKO Health (OPK), Taiwan Semiconductor Manufacturing (TSM) and Meta Platforms (META).

Company Calendar

Last Earnings
5/14/2024
Today
8/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TCON
CIK
1394319
Employees
20
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
$3.73
Trailing P/E Ratio
0.01
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.59 million
Net Margins
N/A
Pretax Margin
145.93%
Return on Equity
-237.65%
Return on Assets
57.29%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.66
Quick Ratio
0.66

Sales & Book Value

Annual Sales
$12.05 million
Price / Sales
0.01
Cash Flow
$1.61 per share
Price / Cash Flow
0.02
Book Value
($0.37) per share
Price / Book
-0.09

Miscellaneous

Outstanding Shares
3,410,000
Free Float
3,228,000
Market Cap
$109.80 thousand
Optionable
No Data
Beta
1.37

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:TCON) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners